Author:
Zanda Emanuele,Busto Natalia,Biancalana Lorenzo,Zacchini Stefano,Biver Tarita,Garcia Begoña,Marchetti Fabio
Funder
Centro de la Fundacio Caixa Castello
Gobierno de Espana Ministerio de Educación Cultura y Deporte
University of Pisa
Junta de Castilla y Leon Consejeria de Educacion
Subject
Toxicology,General Medicine
Reference95 articles.
1. NAMI-A = (ImidazoleH)[trans-RuCl4(κS-DMSO)(κN-Imidazole)]; KP1019 = (IndazoleH)[trans-RuCl4(κN-Indazole)2]); (N)KP1339/IT-139 = Na[trans-RuCl4(κN-Indazole)2]; TLD1433 = (4,4′-dimethyl-2,2′-bipyridine)(α-terthienyl imidazo[4,5-f][1,10]-phenanthroline)ruthenium(II) dichloride.
2. Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy, Invest;Leijen;New Drugs,2015
3. Safety and activity of IT-139, ruthenium-based compound, in patients with advanced solid tumours: a firstin-human, open-label, dose-escalation phase I study with expansion cohort;A Burris;ESMO Open,2016
4. Therapy from a tumor-centered approach: challenges, opportunities, and highlights from the development of TLD1433;Monro;Chem. Rev.,2019
5. NAMI-A and KP1019/1339, two iconic ruthenium anticancer drug candidates face-to-face: a case story in medicinal inorganic chemistry,;Alessio;Molecules,2019
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献